All updates
- Federation of BiH: pembrolizumab and atezolizumab now explicitly for lung cancerWith its decision of 23 September 2026 (Official Gazette of the Federation 76/26), the government changed the entries for pembrolizumab and atezolizumab on the Solidarity Fund list. We checked what this means for lung cancer.
- Serbia: what the RFZO lists from 11 July 2026 pay for in lung cancerLists B and C of the RFZO health insurance fund apply in the version from 11 July 2026. We checked which lung cancer medicines they include, and on what conditions.
- Montenegro: what the October 2026 FZOCG medicines list pays for in lung cancerThe medicines list of the FZOCG health insurance fund is available in its October 2026 version. We checked which lung cancer medicines it includes and who proposes the treatment.
- Albania: what the 2026 FSDKSH list pays for in lung cancerWith decision no. 324 of 6 May 2026, the Council of Ministers set the 2026 medicines list of the FSDKSH health insurance fund. We checked which lung cancer medicines it includes.
- North Macedonia: what the FZOM list pays for in lung cancerWe checked the medicines list of the FZOM health insurance fund in its overview of 7 August 2026. For lung cancer it includes chemotherapy only.
There are no updates for this selection yet.
What we report
- Coverage
- New or changed lists and decisions of the health insurance funds: what is paid, on what conditions and who applies for the treatment. Also when tests start being paid.
- Medicines
- New approvals in the EU or in one of the six countries, new uses in lung cancer, withdrawals and official safety notices. Approved medicines only, no investigational medicines.
- Biomarker tests
- Newly approved tests, labs or hospitals in the region that start offering a test, such as NGS or blood tests, and official changes to which biomarkers should be tested.
- Treatment standard
- Changes to the ESMO or Onkopedia guidelines, including when a new type of treatment becomes standard alongside surgery, radiotherapy and chemotherapy.
- Studies in the region
- Clinical studies that, according to the official trial registry, are taking on participants in one of the six countries: for which change or situation, in which phase and where. Factual, without names of investigational medicines and without results, with a date. The source is the study’s page at Vela Clinical, which links to the registry entry.
- Care near you
- New hospitals, departments and services, for example when a treatment first becomes available in a country, changed booking routes and contacts, and new doctors when the hospital itself announces them.
- Community and support
- New patient organisations, support groups, helplines and support programmes. Only from organisations with their own website or official registration, and no commercial offers.
- Rights and travel
- Changes to entering the EU, such as the start of ETIAS, to sick pay and to the rights for treatment abroad.
What we do not report
We do not report study results, conference news, names of investigational medicines, company news or prices. And nothing without an official source.
How we check
Every update relies on an official source: an authority, a health insurance fund, an official gazette, a guideline, or the hospital or organisation itself.
Before publishing, the hub team checks each update against that source. If a page on this site changes as a result, we update it at the same time.
We check studies in the official trial registry. As the source we link the study’s page at Vela Clinical, which links to the registry entry. Vela Clinical may be paid for referring participants; more under Conflicts of interest.